Date: September 26, 2026

Company & Business Overview

Aarti Drugs Limited is a leading API producer with 50+ molecules across therapeutic categories including antibiotics, antiprotozoals, anti-inflammatories, anti-diabetics, and anti-fungals. The company is the largest global manufacturer of 5 molecules.

Manufacturing Infrastructure

API Segment:

  • 9 manufacturing units contributing ~92% of total revenues
  • Installed capacity: 48,204 MTPA

Formulations Segment (via wholly owned subsidiary):

  • Diversified into formulations in 2014
  • UKMHRA / PICS approved
  • WHO-GMP approved plant in Baddi, Himachal Pradesh
  • Oncology formulation is USFDA approved
  • Installed capacity: 3 billion tablets and 300 million capsules

Specialty Chemicals, Intermediates & Others:

  • Installed capacity: 34,308 MTPA

R&D Initiatives

  • R&D Center at Tarapur supports manufacturing facilities at Tarapur and Sarigam on API process development
  • R&D Center at Turbhe supports development of complex generics for in-house formulation business
  • Developed 30+ APIs (new and existing) in last 5 years
  • R&D Spends: ₹66 Crores (FY26)
  • Staffed by 2 Doctorates, 75 Master Graduates (M.Sc.), and 3 Technicians
  • Developing new age Formulation products for Europe, USA, Australia, Brazil, Canada & Chile
  • Plans to expand R&D capabilities to develop complex Semi solids and Oral liquids

Growth Strategies

  • ₹200 Crore Investment over last 24 months solely for oncology development and pipeline growth
  • Developing robust product pipeline for regulated global markets, leveraging USFDA, MHRA and EDQM approvals
  • Total ~330 regulatory filings submitted across 16 targeted geographies
  • Commenced commercial operations in Latin America and African markets
  • Shifting toward specialized chemistry products with premium pricing
  • Expanding beyond traditional APIs into complex medicine categories

ESG Initiatives

Sustainability Reporting:

  • Published Sustainability Reports for FY 2023-24 (\"Future-Ready: Redefining Sustainability\") and FY 2024-25 (\"From Redefining to Realising Sustainability\")
  • Reports available at: https://www.aartidrugs.com/sustainability-overview

Corporate Social Responsibility (FY 2025-26):

  • Total CSR Spend: ₹414.26 lakhs benefiting over 50,000 lives
  • Education and Skill Development: ₹191.61 lakhs (46.3%, 15,000+ beneficiaries)
  • Healthcare: ₹114.50 lakhs (27.6%)
  • Public Infrastructure: ₹47.71 lakhs (11.5%)
  • Livestock Development: ₹30.00 lakhs (7.2%)
  • Support to Weaker Sections: ₹21.05 lakhs (5.1%)
  • Environment and Water Conservation: ₹9.39 lakhs (2.3%)

Financial Highlights

FY26 Consolidated Financials:

  • Total Revenue: ₹1,950 crore
  • EBITDA: ₹205 crore (10.5% margin)
  • PAT: ₹75 crore
  • Net Worth: ₹1,195 crore
  • Note: EBITDA includes other income; figures exclude ₹11.34 crore of interest income on IT refunds receivable for FY25

Q1 FY27 Consolidated Financials:

  • Total Revenue: ₹495 crore
  • EBITDA: ₹41 crore (8.3% margin)
  • PAT: ₹14 crore
  • Note: All figures include other income; EBITDA and PBT include ~₹2 crores expense of a CWIP write-off

Therapeutic Revenue Split (API Segment)

  • Anti-infective: 47%
  • Gastro-Intestinal: 18%
  • Pain Management: 13%
  • Anti-fungal: 9%
  • Others: 13%

Volume Growth

The company demonstrated consistent volume growth over the past 5 years, though revenue growth was impacted post-Covid due to industry-wide oversupply and sharp API price erosion caused by excessive dumping from China.